cs.AINov 6, 2026

Reinforcement Learning based control of Cancer Chemotherapy treatments

Authors: Jayakody Kankanamalage Chamani Shiranthika

Organizations: Department of Electrical Engineering National Taipei University

Abstract

Reinforcement Learning has achieved tremendous success in recent years. Extending its scope from the traditional complex games such as Atari, Go, Pokeman, and Chess, reinforcement learning has caught researchers' attention on modelling real-life scenarios. Personalized medicine and the dynamic treatment regimen are two such preliminary research fields; researchers are focusing their mindsets currently. Estimating the optimal dynamic treatment regimens from the observational real clinical data is being popularized among the researchers, widening its scope towards more advanced versions of reinforcement learning algorithms. This research is about a research study that focused on reinforcement learning techniques that have been approached in the context of cancer chemotherapy treatments. Primarily this thesis addresses the result of the study by means of the state-of-the-art on reinforcement learning techniques used in generating the optimal policy for sequential treatments, including the existing online reinforcement learning approaches. Thereby a simulation for cancer chemotherapy via traditional Q-learning would be presented. Secondly, the study will extend towards using offline reinforcement learning in the optimal policy generation. Thus, the proposed solution follows a data-driven approach, which works on the real human colon cancer clinical data. The novelty of the proposed solution resides in the implementation of an offline reinforcement learning approach by means of a model-based architecture using the conservative Q-learning and the model-based offline policy optimization algorithm. As per the experimental results and the evaluations, it was revealed that the proposed Chemo RL model caters well the problem of cancer chemotherapy treatment scheduling and serves as a supportive model for the junior oncologists in deciding their treatment decisions.

Explore similar work

Sep 10, 2026

Adaptive Chemotherapy Control under Tumor Heterogeneity via Reinforcement Learning

Designing effective chemotherapy regimens is hindered by tumor heterogeneity and drug resistance, which complicate the deployment of patient-specific model-based optimal control across diverse populations. We develop and compare closed-loop deep reinforcement learning (DRL) dosing policies with continuous (TD3) and discrete (DQN) action spaces trained on a high-dimensional heterogeneous tumor model. The DRL policies are benchmarked against a Pontryagin's Maximum Principle (PMP)-derived open-loop benchmark. We assess generalization under parametric heterogeneity using a 100-patient virtual cohort with plus or minus 10 percent uniform perturbations in growth and drug-sensitivity parameters. Across this cohort, TD3 achieves higher average tumor reduction, while DQN yields tighter inter-patient dosing consistency, revealing a clear efficacy-consistency trade-off in this study. Our simulations assume full observation of all tumor subpopulations; translation to sparse and noisy clinical measurements will require partial-observability formulations and/or state estimation. Overall, the results show that simulation-trained DRL can learn state-dependent feedback dosing policies that complement open-loop optimal control benchmarks.
May 4, 2026

Recurrent Deep Reinforcement Learning for Chemotherapy Control under Partial Observability

Chemotherapy dose optimization can be formulated as a dynamic treatment regime, requiring sequential decisions under uncertainty that must balance tumor suppression against toxicity. However, most reinforcement learning approaches assume full observability of the patient state, a condition rarely met in clinical practice. We investigate whether memory-augmented policies can improve chemotherapy control under partial observability. To this end, we employ a recurrent TD3-based approach with separate LSTM actor-critic networks and evaluate it on the AhnChemoEnv benchmark from DTR-Bench, considering both off-policy and on-policy recurrent architectures against feed-forward TD3 and Soft Actor-Critic. Pharmacokinetic and pharmacodynamic variability are held fixed to isolate hidden-state uncertainty and observation noise and to avoid confounding effects from inter-patient variability. Across ten random seeds, recurrence yields modest benefit under full observability but substantially stronger and more stable performance under partial observability, with more consistent tumor suppression and improved normal-cell preservation. These findings indicate that memory-based policies are particularly beneficial when clinically relevant state information is incomplete or noisy.
Oct 12, 2026

Reinforcement Learning In Partially Verifiable Environments for Colon Cancer Treatment Planning

Clinical decision-making is a sequential process of information collection, clinical inference, and forecasting under partial observability, often without a uniquely correct treatment decision. Large language models (LLMs) have demonstrated strong medical question-answering capabilities but extending these advances to clinical reasoning remains challenging because many clinical tasks are only partially verifiable. Recent clinical reinforcement learning (RL) work has therefore largely focused on diagnostic endpoints, where correctness can be more directly verified. Oncology treatment decision making is a particularly challenging instance of this problem that extends beyond medical question-answering in which multiple decision trajectories can be clinically defensible for the same partially observed patient state. We formulate oncology treatment planning as an interactive RL problem under partial observability and construct patient-specific, process-aware rewards from decision processes observed in real world clinical records. The agent must learn to sequentially acquire information from a structured patient representation before committing to a first-line treatment recommendation, and is evaluated on information gathering, treatment selection, and reasoning alignment. Using GRPO and GDPO to optimize Llama-3.1-8B-Instruct within this environment, RL substantially improves the base policy beyond frontier model capabilities. The GDPO-trained policy increases Mean@3 scalar clinical reward by 79.60%79.60\% over base Llama and exceeds GPT-5.2 by 18.82%18.82\% under the same interactive environment, while reducing query count during training. Overall, our results show that patient-specific, partially verifiable rewards can provide an effective learning signal for interactive clinical RL when both the patient state and the underlying clinical decision process are only partially observed.